Marki Microwave Expands Millimeter Wave Portfolio with Series of High Performance Integrated Drive Mixers
27.9.2022 09:50:00 EEST | Business Wire | Press release
European Microwave Week – Marki Microwave®, innovator in the radio frequency and microwave industry for over 30 years, today announced the expansion of its millimeter wave (mmWave) portfolio with a series of leading-edge mixers featuring integrated local oscillator (LO) drivers. Ideal for space constrained applications requiring wide bandwidths and operation at mmWave frequencies, the integrated drive mixers reduce size, weight, power and cost (SWaP-C) while simplifying overall integration of the LO path for ease of use and optimized performance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005833/en/
Marki Microwave's versatile, broadband double balanced mixers feature an integrated LO driver amplifier, which allows for operation with LO powers as low as -6 dBm. (Graphic: Business Wire)
“For customers needing to realize the best performance in a small footprint with reduced design effort, our latest integrated drive mixers are game changers,” said Duncan Pilgrim, vice president of sales and marketing at Marki Microwave. “The designs deliver high performance across a wide bandwidth with reduced drive requirements, promising ease of use in a traditionally complex design space.”
The MM1A-0832HPSM, MM1A-1040HPSM and MM1A-1855HPSM are versatile, broadband double balanced mixers featuring an integrated LO driver amplifier, which allows for operation with LO powers as low as -6 dBm. Unlike traditional industry solutions using discrete packages, which often suffer from subpar performance, Marki Microwave’s co-packaging utilizes optimal die technology for the amplifier and mixer functions. The new technique eliminates the need for a separate amplifier and mixer interface, minimizing design costs without sacrificing performance across the operating bandwidth. The new integrated drive mixers’ exceptional conversion loss and linearity combined with their compact footprint make the parts an ideal solution for high performance test and measurement, aerospace and defense, telecom infrastructure and satellite designs.
Availability
The MM1A-0832HPSM, MM1A-1040HPSM and MM1A-1855HPSM will be available in October in 3 x 4.6 mm QFN packages. Specifications subject to change without notice. For samples and sales information, contact sales@markimicrowave.com.
About Marki Microwave
For over 30 years, Marki Microwave has solved its customers’ most complex problems by creating a robust portfolio of performance shattering RF and microwave components. Founded in 1991 with the goal to develop the best mixers in the industry, Marki Microwave now has the highest performance portfolio of broadband mixers, spanning frequencies from 10 MHz to 130 GHz+ in die, surface mount and connectorized form factors. Today, Marki Microwave is a single source for high performance, broadband microwave products, supporting multiple form factors including die, surface mount and connectorized solutions for the entire RF block diagram. As demands from RF and microwave markets continue to evolve and the supply base consolidates, Marki Microwave remains dedicated to building beyond performance barriers, expanding its catalog and empowering the industry to build next-generation systems. For more information, visit www.markimicrowave.com.
© 2022. Marki Microwave, Inc. All Rights Reserved. Marki Microwave, the Marki logo, and T3 Mixer are trademarks or registered trademarks of Marki Microwave, Inc., in the U.S. and other countries. All other trademarks are property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220926005833/en/
Contact information
Media Contact
Olivia Metcalfe
Marki Microwave
pr@markimicrowave.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Serviceplan Group Deploys Creative AI Across Global Operations in Partnership With Luma AI19.2.2026 12:00:00 EET | Press release
Serviceplan Group today announced a strategic partnership with Luma AI to deploy AI for creative work across the agency group’s global operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219346568/en/ Serviceplan Group today announced a strategic partnership with Luma AI to deploy AI for creative work across the agency group’s global operations. Shown here (L-R) Alex Schill, Global Chief Creative Officer of Serviceplan Group, Jason Day, Head of EMEA for Luma AI, Amit Jain, Co-Founder and CEO of Luma AI, and Florian Haller, CEO of Serviceplan Group. Under the agreement, Luma AI will serve as Serviceplan Group’s AI technology partner, embedding AI for creative work into professional workflows spanning strategy, creative development, content production, and delivery. The rollout marks a significant operational milestone for Serviceplan Group, positioning it as the first of the world’s largest agency groups to standard
GekkoVet and Royal Canin Enter Latin America with Mexico Launch, Opening a New Continent in their Global Partnership19.2.2026 11:59:00 EET | Press release
GekkoVet, the Finnish leader in AI-powered clinical decision support for veterinarians, and Royal Canin, a global pioneer in pet health through nutrition, announce the launch of their strategic collaboration in Mexico. This marks the first national rollout of their partnership in Latin America, expanding the initiative that began earlier this year with successful deployments in Asia. Royal Canin Mexico is equipping veterinary teams with GekkoVet’s intelligent platform, which provides real-time diagnostic assistance, treatment recommendations, and drug information. The collaboration aims to enhance clinical efficiency, improve patient outcomes, and support veterinarians with evidence-based tools that integrate seamlessly into daily practice. “This launch in Mexico is a major step forward—not just regionally, but globally,” said Johanna Majamaa, DVM and co-founder of GekkoVet. “After strong momentum in Asia, entering Latin America opens a new chapter in our mission to empower veterinaria
Vonage Expands Developer Ecosystem to Accelerate the Next Era of Enterprise Digital Transformation19.2.2026 11:08:00 EET | Press release
Vonage, part of Ericsson (NASDAQ: ERIC), today announced a number of new initiatives, to further expand and enable its global developer community. By growing its developer community and tools, giving developers and enterprises access to new mobile network insights and capabilities that can be embedded into existing applications and workflows, Vonage is accelerating its strategy to transform mobile networks into a programmable platform. Putting Vonage APIs in the Hands of 40 million+ More Developers Vonage is announcing the launch of its Verified Workspace on the Postman API Network, making Vonage APIs available to the 40+ million developers who use Postman. The new, verified workspace gives Postman’s community of global developer members certified access to Vonage’s portfolio of Network APIs, Communications APIs, and developer tools - enabling them to copy, or fork, collections into their own workspaces and build, test, and collaborate in real time with other developers and teams. This
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 09:50:00 EET | Press release
Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto
ENHERTU ® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 09:30:00 EET | Press release
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use (CHMP). The application is based on data from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. In the trial, ENHERTU demo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom